Evaluation of the CD123 Expression and FLT3 Gene Mutations in Patients with Acute Myeloid Leukemia

Background and Objective: Identification of cytogenetic and molecular changes plays an important role in acute myeloid leukemia (AML) patients. Thus, they are used in classification, prognosis and treatment of the disease. The CD123 expression and FLT3 gene mutations are also the variations that may assist in prognosis and treatment of patients with AML. Methods: This study was performed on 76 patients as new cases of AML. The correlation between CD123 immunohistochemical (IHC) expression and FLT3 gene mutations with each other as well as morphological, immunophenotypical and cytogenetic factors was studied. Results: The results represented the CD123 IHC expression in 55.3% and FLT3 gene mutations in 28.9% of cases. We found that 81.3% of patients who had FLT3/ITD gene mutations revealed IHC of CD123 expression (P=0.019). The CD123 expression against FLT3 was also correlated with monocytic differentiation in bone marrow blasts (P=0.031). There were significant correlations between IHC expression of CD123 and FLT3/ITD mutations with a high percentage of aspirated bone marrow blasts (P=0.01 and P=0.006, respectively) as well as the lack of CD34 expression in bone marrow blasts (P=0.007 and P=0.021, respectively). Conclusion: The CD123 IHC positive AMLs were correlated with certain pathologic features, some of which can be similar with correlations of background mutation of FLT3/ITD; According to the negative predictive value (NPV), 88.2% of CD123 IHC showed FLT3 gene mutation. In addition to its use in targeted therapy, it could be a marker to decide what molecular tests to use in the next steps.

[1]  N. Bailey,et al.  Acute Myeloid Leukemia Genetics: Risk Stratification and Implications for Therapy. , 2015, Archives of pathology & laboratory medicine.

[2]  Yechen Xiao,et al.  CD123 and its potential clinical application in leukemias. , 2015, Life sciences.

[3]  G. Ehninger,et al.  Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia , 2014, Blood Cancer Journal.

[4]  M. Levis.  FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? , 2013, Hematology. American Society of Hematology. Education Program.

[5]  M. Boyiadzis,et al.  CD123 Immunohistochemical Expression in Acute Myeloid Leukemia is Associated With Underlying FLT3-ITD and NPM1 Mutations , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[6]  E. Estey,et al.  Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management , 2012, American journal of hematology.

[7]  J. Tamburini,et al.  High levels of CD34+CD38low/−CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study , 2011, Haematologica.

[8]  Rachid,et al.  A population-based study of the epidemiology and clinical features of adults with acute myeloid leukemia in Algeria: report on behalf of the Algerian Acute Leukemia Study Group. , 2011, Hematology/oncology and stem cell therapy.

[9]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[10]  A. Mackensen,et al.  Novel conjugates of single‐chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells , 2010, British journal of haematology.

[11]  E. Blennow,et al.  Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia , 2009, Haematologica.

[12]  R. Foà,et al.  Interleukin (IL)‐3/granulocyte macrophage‐colony stimulating factor/IL‐5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS‐related tyrosine kinase 3 receptor , 2009, British journal of haematology.

[13]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[14]  A. Orazi.  Histopathology in the Diagnosis and Classification of Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Myelodysplastic/Myeloproliferative Diseases , 2007, Pathobiology.

[15]  M. Lübbert,et al.  Acute Myeloid Leukemia: Epidemiology and Etiology , 2006, Cancer.

[16]  C. D. Wu,et al.  Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22). , 2006, American journal of clinical pathology.

[17]  D. Forman,et al.  Cancer prevalence in the UK: results from the EUROPREVAL study. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  E. Coccia,et al.  Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. , 2002, Blood.

[19]  D. Howard,et al.  The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.

[20]  Angel F. Lopez,et al.  Mechanism of Activation of the GM‐CSF, IL‐3, and IL‐5 Family of Receptors , 1998, Stem cells.

[21]  J. Ross,et al.  Epidemiology of acute leukemia in children and adults. , 1997, Seminars in oncology.

[22]  A. Monabati,et al.  Evaluation of the CD 123 Expression and FLT 3 Gene Mutations in Patients with Acute Myeloid Leukemia , 2018 .

[23]  T. Haferlach,et al.  Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype. , 2012, Leukemia research.

[24]  H. Drexler,et al.  FLT3 mutations in acute myeloid leukemia cell lines , 2003, Leukemia.

[25]  A. Aventín,et al.  Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. , 2001, Haematologica.